Related Experiment Video
Updated: Jun 16, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Feasibility of sequential high-dose chemotherapy in advanced pediatric solid tumors
Seung Yeon Kwon1, Sung Chul Won, Jung Woo Han
1Department of Pediatric Hematology-Oncology, Yonsei University College of Medicine, Seoul, Korea.
Pediatric Hematology and Oncology
|February 4, 2010
Summary
This study explored sequential high-dose chemotherapy (HDCT) for advanced pediatric solid tumors. The treatment showed promising tumor response and feasibility in young patients, with many achieving remission.
Area of Science:
- Pediatric Oncology
- Hematology
- Stem Cell Transplantation
Background:
- Advanced pediatric solid tumors present significant treatment challenges.
- Sequential high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell (HSC) infusion is an intensive therapeutic approach.
Purpose of the Study:
- To assess the feasibility and tumor response of a 3-cycle sequential HDCT regimen in pediatric patients with advanced solid tumors.
Main Methods:
- Retrospective review of medical records for 11 pediatric patients.
- Two initial courses of reduced-intensity conditioning HDCT followed by a final HDCT with autologous HSC infusion.
- Monitoring of neutrophil recovery and toxic reactions.
Main Results:
- Median time to absolute neutrophil count recovery was 12-13 days across cycles.
- Common toxicities included fever, infection, and vomiting; one patient experienced transplantation-related mortality.
- Nine patients demonstrated complete or partial tumor response at 6 months post-therapy.
- Six patients remained alive with no evidence of disease at a median 24-month follow-up.
Conclusions:
- Sequential HDCT appears to be a feasible treatment option for advanced pediatric solid tumors.
- The regimen showed encouraging tumor response rates and long-term survival in this preliminary study.
- Further investigation is warranted to confirm these findings in a larger cohort.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...